Brussels Seeks UNESCO Heritage Mark for Puppetry, Flower Carpet

Puppets are seen at the Royal Toone Theatre, in Brussels, Belgium, March 28, 2024. REUTERS/Yves Herman
Puppets are seen at the Royal Toone Theatre, in Brussels, Belgium, March 28, 2024. REUTERS/Yves Herman
TT

Brussels Seeks UNESCO Heritage Mark for Puppetry, Flower Carpet

Puppets are seen at the Royal Toone Theatre, in Brussels, Belgium, March 28, 2024. REUTERS/Yves Herman
Puppets are seen at the Royal Toone Theatre, in Brussels, Belgium, March 28, 2024. REUTERS/Yves Herman

Brussels is looking to protect two of its historical traditions: rod puppetry and a 1,680-square-meter flower carpet rolled out every second year in front of the Belgian capital's city hall, by granting them the UNESCO intangible cultural heritage status.
"Those two things are really part of our heritage, of our identity, they're part of our folklore, and we want to make sure they are preserved for the future," said the city's state secretary for heritage, Ans Persoons.
"When we think of protecting the past it should not only be about bricks and architecture but it should also be about our traditions and our culture."
Following the filings, UNESCO designations might follow in December, 2025, Reuters said.
Nicolas Geal, whose family theater is the only Brussels venue keeping the centuries-old tradition of rod puppetry alive, said the UNESCO listing might save the art form from oblivion.
"This way, maybe some other people will start new initiatives," said Geal, speaking in his Theatre Toone, which sits in Brussels' historical center and features several shows a week, its repertoire ranging from Dracula to Faust.
The rod puppetry tradition originates from traveling carnival theaters in the Renaissance and was widely popular during the 19th century. Nowadays, puppeteers concealed behind a screen bring puppets to life during shows by pulling their rods.
Just a stone's throw away is the city's fabled historic main square, or Grand Place, the setting for the biennale flower carpet tradition that attracts some 200,000 spectators each time.
Brussels laid its first flower carpet - a scented display that tracks its origins to Mediterranean countries in the 14th century - some 50 years ago. The next one is due in August, with around half a million begonias or dahlias for the design.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”